Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up

Background: Moderate‐to‐large residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience in patients of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Catheterization and cardiovascular interventions 2010-07, Vol.76 (1), p.145-150
Hauptverfasser: Diaz, Tulio, Cubeddu, Roberto J., Rengifo-Moreno, Pablo A., Cruz-Gonzalez, Ignacio, Solis-Martin, Jorge, Buonanno, Ferdinando S., Inglessis, Ignacio, Palacios, Igor F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 150
container_issue 1
container_start_page 145
container_title Catheterization and cardiovascular interventions
container_volume 76
creator Diaz, Tulio
Cubeddu, Roberto J.
Rengifo-Moreno, Pablo A.
Cruz-Gonzalez, Ignacio
Solis-Martin, Jorge
Buonanno, Ferdinando S.
Inglessis, Ignacio
Palacios, Igor F.
description Background: Moderate‐to‐large residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience in patients of these patients with a prior history of cryptogenic stroke and/or transient ischemic attack (TIA). Methods: All patients undergoing percutaneous PFO closure were routinely screened at six‐months for residual shunts using transthoracic 2D echocardiography with antecubital administration of agitated saline contrast and color flow Doppler. Patients with evidence of moderate‐to‐large residual shunts were selected to undergo reintervention with shunt closure. Postreintervention follow‐up was performed at 24‐hr, 30 days, and every six months thereafter. Clinical predictors of the moderate‐to‐large residual shunts, and the feasibility, safety and long‐term efficacy of percutaneous residual shunt closure using a second device implant were examined. Results: Between 1995 and 2007, a total of 424 patients underwent PFO closure. Of these, 5% (21/424) had moderate‐to‐large residual shunts. Baseline characteristics among patients with moderate‐to‐large residual shunts and those with only none or small defects (n = 403) were similar. Multivariate analysis identified the 24‐hr postprocedure shunt as the only independent predictor of residual shunting at six months. Of the 21 study patients with moderate‐to‐large residual shunt (mean age, 47 ± 14), one underwent successful elective surgical repair, while the remaining 20 underwent transcatheter closure using a second device. The technique was successful in 95% (19/20), and all but one patient had complete shunt closure at six months of their percutaneous reintervention. We report no deaths, recurrent strokes or TIAs during the long‐term mean follow‐up period of 2.9 years. Conclusions: Our study suggests that in patients with moderate‐to‐large residual PFO shunts, percutaneous reintervention using a second device implant is safe and effective. © 2010 Wiley‐Liss, Inc.
doi_str_mv 10.1002/ccd.22475
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733568134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733568134</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3625-4a752a96d46a7b80f6a6de2be74abc91403fe6f6641759874047a34ac66eafb3</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi0EohdY8ALIO8QireM49oRdFWhBGgoSlcrOOnGOpwbnUjth2jfp4-Ih0-5Y2Tr6_k865yfkTc5Ocsb4qTHtCedClc_IYV5ynikufz7f__NKyANyFOMvxlglefWSHHBWqlWKHpKHr9DDBjvsJzpYGjC6dgZP483cT5GCnTBQ17vJpeGIwcwT9DjMkY4w7UJ2CJDSdPgDHqnxQ5wDfqBnNLp-s5skKCnwLoUd9gbp1k031HUdti4pKPQt9UO_yRLWJZ33wzabx1fkhQUf8fX-PSZX55-u6s_Z-tvFl_psnZlC8jIToEoOlWyFBNWsmJUgW-QNKgGNqXLBCovSSilyVVYrJZhQUAgwUiLYpjgm7xbtGIbbGeOkOxcNer9sqVVRlHKVFyKR7xfShCHGgFaPwXUQ7nXO9K4GnWrQ_2pI7Nu9dW7Snk_k490TcLoAW-fx_v8mXdcfH5XZknBxwrunBITfWqoikdeXF_py_f1HzdW1Pi_-Am1wpAU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733568134</pqid></control><display><type>article</type><title>Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Diaz, Tulio ; Cubeddu, Roberto J. ; Rengifo-Moreno, Pablo A. ; Cruz-Gonzalez, Ignacio ; Solis-Martin, Jorge ; Buonanno, Ferdinando S. ; Inglessis, Ignacio ; Palacios, Igor F.</creator><creatorcontrib>Diaz, Tulio ; Cubeddu, Roberto J. ; Rengifo-Moreno, Pablo A. ; Cruz-Gonzalez, Ignacio ; Solis-Martin, Jorge ; Buonanno, Ferdinando S. ; Inglessis, Ignacio ; Palacios, Igor F.</creatorcontrib><description>Background: Moderate‐to‐large residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience in patients of these patients with a prior history of cryptogenic stroke and/or transient ischemic attack (TIA). Methods: All patients undergoing percutaneous PFO closure were routinely screened at six‐months for residual shunts using transthoracic 2D echocardiography with antecubital administration of agitated saline contrast and color flow Doppler. Patients with evidence of moderate‐to‐large residual shunts were selected to undergo reintervention with shunt closure. Postreintervention follow‐up was performed at 24‐hr, 30 days, and every six months thereafter. Clinical predictors of the moderate‐to‐large residual shunts, and the feasibility, safety and long‐term efficacy of percutaneous residual shunt closure using a second device implant were examined. Results: Between 1995 and 2007, a total of 424 patients underwent PFO closure. Of these, 5% (21/424) had moderate‐to‐large residual shunts. Baseline characteristics among patients with moderate‐to‐large residual shunts and those with only none or small defects (n = 403) were similar. Multivariate analysis identified the 24‐hr postprocedure shunt as the only independent predictor of residual shunting at six months. Of the 21 study patients with moderate‐to‐large residual shunt (mean age, 47 ± 14), one underwent successful elective surgical repair, while the remaining 20 underwent transcatheter closure using a second device. The technique was successful in 95% (19/20), and all but one patient had complete shunt closure at six months of their percutaneous reintervention. We report no deaths, recurrent strokes or TIAs during the long‐term mean follow‐up period of 2.9 years. Conclusions: Our study suggests that in patients with moderate‐to‐large residual PFO shunts, percutaneous reintervention using a second device implant is safe and effective. © 2010 Wiley‐Liss, Inc.</description><identifier>ISSN: 1522-1946</identifier><identifier>EISSN: 1522-726X</identifier><identifier>DOI: 10.1002/ccd.22475</identifier><identifier>PMID: 20578100</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Boston ; Cardiac Catheterization - adverse effects ; Cardiac Catheterization - instrumentation ; Catheterization ; CHDA ; CHDA, congenital heart disease in adults ; Chi-Square Distribution ; congenital heart disease in adults ; Echocardiography, Doppler, Color ; Female ; FIST ; FIST, fistula/shunts ; fistula/shunts ; Foramen Ovale, Patent - complications ; Foramen Ovale, Patent - diagnostic imaging ; Foramen Ovale, Patent - physiopathology ; Foramen Ovale, Patent - therapy ; Hemodynamics ; Humans ; Ischemic Attack, Transient - etiology ; Ischemic Attack, Transient - physiopathology ; Ischemic Attack, Transient - prevention &amp; control ; Logistic Models ; Male ; Middle Aged ; ovale/atrial septal defect ; patent foramen ; PFO ; PFO, patent foramen ; Risk Assessment ; Risk Factors ; Septal Occluder Device ; Stroke - etiology ; Stroke - physiopathology ; Stroke - prevention &amp; control ; Time Factors ; Treatment Outcome ; Young Adult</subject><ispartof>Catheterization and cardiovascular interventions, 2010-07, Vol.76 (1), p.145-150</ispartof><rights>Copyright © 2010 Wiley‐Liss, Inc.</rights><rights>(c) 2010 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3625-4a752a96d46a7b80f6a6de2be74abc91403fe6f6641759874047a34ac66eafb3</citedby><cites>FETCH-LOGICAL-c3625-4a752a96d46a7b80f6a6de2be74abc91403fe6f6641759874047a34ac66eafb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fccd.22475$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fccd.22475$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20578100$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Diaz, Tulio</creatorcontrib><creatorcontrib>Cubeddu, Roberto J.</creatorcontrib><creatorcontrib>Rengifo-Moreno, Pablo A.</creatorcontrib><creatorcontrib>Cruz-Gonzalez, Ignacio</creatorcontrib><creatorcontrib>Solis-Martin, Jorge</creatorcontrib><creatorcontrib>Buonanno, Ferdinando S.</creatorcontrib><creatorcontrib>Inglessis, Ignacio</creatorcontrib><creatorcontrib>Palacios, Igor F.</creatorcontrib><title>Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up</title><title>Catheterization and cardiovascular interventions</title><addtitle>Cathet. Cardiovasc. Intervent</addtitle><description>Background: Moderate‐to‐large residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience in patients of these patients with a prior history of cryptogenic stroke and/or transient ischemic attack (TIA). Methods: All patients undergoing percutaneous PFO closure were routinely screened at six‐months for residual shunts using transthoracic 2D echocardiography with antecubital administration of agitated saline contrast and color flow Doppler. Patients with evidence of moderate‐to‐large residual shunts were selected to undergo reintervention with shunt closure. Postreintervention follow‐up was performed at 24‐hr, 30 days, and every six months thereafter. Clinical predictors of the moderate‐to‐large residual shunts, and the feasibility, safety and long‐term efficacy of percutaneous residual shunt closure using a second device implant were examined. Results: Between 1995 and 2007, a total of 424 patients underwent PFO closure. Of these, 5% (21/424) had moderate‐to‐large residual shunts. Baseline characteristics among patients with moderate‐to‐large residual shunts and those with only none or small defects (n = 403) were similar. Multivariate analysis identified the 24‐hr postprocedure shunt as the only independent predictor of residual shunting at six months. Of the 21 study patients with moderate‐to‐large residual shunt (mean age, 47 ± 14), one underwent successful elective surgical repair, while the remaining 20 underwent transcatheter closure using a second device. The technique was successful in 95% (19/20), and all but one patient had complete shunt closure at six months of their percutaneous reintervention. We report no deaths, recurrent strokes or TIAs during the long‐term mean follow‐up period of 2.9 years. Conclusions: Our study suggests that in patients with moderate‐to‐large residual PFO shunts, percutaneous reintervention using a second device implant is safe and effective. © 2010 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Boston</subject><subject>Cardiac Catheterization - adverse effects</subject><subject>Cardiac Catheterization - instrumentation</subject><subject>Catheterization</subject><subject>CHDA</subject><subject>CHDA, congenital heart disease in adults</subject><subject>Chi-Square Distribution</subject><subject>congenital heart disease in adults</subject><subject>Echocardiography, Doppler, Color</subject><subject>Female</subject><subject>FIST</subject><subject>FIST, fistula/shunts</subject><subject>fistula/shunts</subject><subject>Foramen Ovale, Patent - complications</subject><subject>Foramen Ovale, Patent - diagnostic imaging</subject><subject>Foramen Ovale, Patent - physiopathology</subject><subject>Foramen Ovale, Patent - therapy</subject><subject>Hemodynamics</subject><subject>Humans</subject><subject>Ischemic Attack, Transient - etiology</subject><subject>Ischemic Attack, Transient - physiopathology</subject><subject>Ischemic Attack, Transient - prevention &amp; control</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>ovale/atrial septal defect</subject><subject>patent foramen</subject><subject>PFO</subject><subject>PFO, patent foramen</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Septal Occluder Device</subject><subject>Stroke - etiology</subject><subject>Stroke - physiopathology</subject><subject>Stroke - prevention &amp; control</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1522-1946</issn><issn>1522-726X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1DAUhi0EohdY8ALIO8QireM49oRdFWhBGgoSlcrOOnGOpwbnUjth2jfp4-Ih0-5Y2Tr6_k865yfkTc5Ocsb4qTHtCedClc_IYV5ynikufz7f__NKyANyFOMvxlglefWSHHBWqlWKHpKHr9DDBjvsJzpYGjC6dgZP483cT5GCnTBQ17vJpeGIwcwT9DjMkY4w7UJ2CJDSdPgDHqnxQ5wDfqBnNLp-s5skKCnwLoUd9gbp1k031HUdti4pKPQt9UO_yRLWJZ33wzabx1fkhQUf8fX-PSZX55-u6s_Z-tvFl_psnZlC8jIToEoOlWyFBNWsmJUgW-QNKgGNqXLBCovSSilyVVYrJZhQUAgwUiLYpjgm7xbtGIbbGeOkOxcNer9sqVVRlHKVFyKR7xfShCHGgFaPwXUQ7nXO9K4GnWrQ_2pI7Nu9dW7Snk_k490TcLoAW-fx_v8mXdcfH5XZknBxwrunBITfWqoikdeXF_py_f1HzdW1Pi_-Am1wpAU</recordid><startdate>20100701</startdate><enddate>20100701</enddate><creator>Diaz, Tulio</creator><creator>Cubeddu, Roberto J.</creator><creator>Rengifo-Moreno, Pablo A.</creator><creator>Cruz-Gonzalez, Ignacio</creator><creator>Solis-Martin, Jorge</creator><creator>Buonanno, Ferdinando S.</creator><creator>Inglessis, Ignacio</creator><creator>Palacios, Igor F.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100701</creationdate><title>Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up</title><author>Diaz, Tulio ; Cubeddu, Roberto J. ; Rengifo-Moreno, Pablo A. ; Cruz-Gonzalez, Ignacio ; Solis-Martin, Jorge ; Buonanno, Ferdinando S. ; Inglessis, Ignacio ; Palacios, Igor F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3625-4a752a96d46a7b80f6a6de2be74abc91403fe6f6641759874047a34ac66eafb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Boston</topic><topic>Cardiac Catheterization - adverse effects</topic><topic>Cardiac Catheterization - instrumentation</topic><topic>Catheterization</topic><topic>CHDA</topic><topic>CHDA, congenital heart disease in adults</topic><topic>Chi-Square Distribution</topic><topic>congenital heart disease in adults</topic><topic>Echocardiography, Doppler, Color</topic><topic>Female</topic><topic>FIST</topic><topic>FIST, fistula/shunts</topic><topic>fistula/shunts</topic><topic>Foramen Ovale, Patent - complications</topic><topic>Foramen Ovale, Patent - diagnostic imaging</topic><topic>Foramen Ovale, Patent - physiopathology</topic><topic>Foramen Ovale, Patent - therapy</topic><topic>Hemodynamics</topic><topic>Humans</topic><topic>Ischemic Attack, Transient - etiology</topic><topic>Ischemic Attack, Transient - physiopathology</topic><topic>Ischemic Attack, Transient - prevention &amp; control</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>ovale/atrial septal defect</topic><topic>patent foramen</topic><topic>PFO</topic><topic>PFO, patent foramen</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Septal Occluder Device</topic><topic>Stroke - etiology</topic><topic>Stroke - physiopathology</topic><topic>Stroke - prevention &amp; control</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Diaz, Tulio</creatorcontrib><creatorcontrib>Cubeddu, Roberto J.</creatorcontrib><creatorcontrib>Rengifo-Moreno, Pablo A.</creatorcontrib><creatorcontrib>Cruz-Gonzalez, Ignacio</creatorcontrib><creatorcontrib>Solis-Martin, Jorge</creatorcontrib><creatorcontrib>Buonanno, Ferdinando S.</creatorcontrib><creatorcontrib>Inglessis, Ignacio</creatorcontrib><creatorcontrib>Palacios, Igor F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Catheterization and cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Diaz, Tulio</au><au>Cubeddu, Roberto J.</au><au>Rengifo-Moreno, Pablo A.</au><au>Cruz-Gonzalez, Ignacio</au><au>Solis-Martin, Jorge</au><au>Buonanno, Ferdinando S.</au><au>Inglessis, Ignacio</au><au>Palacios, Igor F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up</atitle><jtitle>Catheterization and cardiovascular interventions</jtitle><addtitle>Cathet. Cardiovasc. Intervent</addtitle><date>2010-07-01</date><risdate>2010</risdate><volume>76</volume><issue>1</issue><spage>145</spage><epage>150</epage><pages>145-150</pages><issn>1522-1946</issn><eissn>1522-726X</eissn><abstract>Background: Moderate‐to‐large residual shunts following percutaneous patent foramen ovale (PFO) closure are clinically important and associated with recurrent neuroembolic events. However, their management has not been clearly established in clinical practice. We report our experience in patients of these patients with a prior history of cryptogenic stroke and/or transient ischemic attack (TIA). Methods: All patients undergoing percutaneous PFO closure were routinely screened at six‐months for residual shunts using transthoracic 2D echocardiography with antecubital administration of agitated saline contrast and color flow Doppler. Patients with evidence of moderate‐to‐large residual shunts were selected to undergo reintervention with shunt closure. Postreintervention follow‐up was performed at 24‐hr, 30 days, and every six months thereafter. Clinical predictors of the moderate‐to‐large residual shunts, and the feasibility, safety and long‐term efficacy of percutaneous residual shunt closure using a second device implant were examined. Results: Between 1995 and 2007, a total of 424 patients underwent PFO closure. Of these, 5% (21/424) had moderate‐to‐large residual shunts. Baseline characteristics among patients with moderate‐to‐large residual shunts and those with only none or small defects (n = 403) were similar. Multivariate analysis identified the 24‐hr postprocedure shunt as the only independent predictor of residual shunting at six months. Of the 21 study patients with moderate‐to‐large residual shunt (mean age, 47 ± 14), one underwent successful elective surgical repair, while the remaining 20 underwent transcatheter closure using a second device. The technique was successful in 95% (19/20), and all but one patient had complete shunt closure at six months of their percutaneous reintervention. We report no deaths, recurrent strokes or TIAs during the long‐term mean follow‐up period of 2.9 years. Conclusions: Our study suggests that in patients with moderate‐to‐large residual PFO shunts, percutaneous reintervention using a second device implant is safe and effective. © 2010 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>20578100</pmid><doi>10.1002/ccd.22475</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1522-1946
ispartof Catheterization and cardiovascular interventions, 2010-07, Vol.76 (1), p.145-150
issn 1522-1946
1522-726X
language eng
recordid cdi_proquest_miscellaneous_733568134
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Adult
Aged
Boston
Cardiac Catheterization - adverse effects
Cardiac Catheterization - instrumentation
Catheterization
CHDA
CHDA, congenital heart disease in adults
Chi-Square Distribution
congenital heart disease in adults
Echocardiography, Doppler, Color
Female
FIST
FIST, fistula/shunts
fistula/shunts
Foramen Ovale, Patent - complications
Foramen Ovale, Patent - diagnostic imaging
Foramen Ovale, Patent - physiopathology
Foramen Ovale, Patent - therapy
Hemodynamics
Humans
Ischemic Attack, Transient - etiology
Ischemic Attack, Transient - physiopathology
Ischemic Attack, Transient - prevention & control
Logistic Models
Male
Middle Aged
ovale/atrial septal defect
patent foramen
PFO
PFO, patent foramen
Risk Assessment
Risk Factors
Septal Occluder Device
Stroke - etiology
Stroke - physiopathology
Stroke - prevention & control
Time Factors
Treatment Outcome
Young Adult
title Management of residual shunts after initial percutaneous patent foramen ovale closure: A single center experience with immediate and long-term follow-up
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T01%3A36%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20residual%20shunts%20after%20initial%20percutaneous%20patent%20foramen%20ovale%20closure:%20A%20single%20center%20experience%20with%20immediate%20and%20long-term%20follow-up&rft.jtitle=Catheterization%20and%20cardiovascular%20interventions&rft.au=Diaz,%20Tulio&rft.date=2010-07-01&rft.volume=76&rft.issue=1&rft.spage=145&rft.epage=150&rft.pages=145-150&rft.issn=1522-1946&rft.eissn=1522-726X&rft_id=info:doi/10.1002/ccd.22475&rft_dat=%3Cproquest_cross%3E733568134%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733568134&rft_id=info:pmid/20578100&rfr_iscdi=true